Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| BAY 73-4506 | BAY 73-4506 Inhibitor. Uses: Scientific use. Product Category: T1792. CAS No. 755037-03-7. |  |
| Regorafenib | Inhibits PDGFR tyrosine kinase with IC50=83nM. It is useful for the treatment of inflammation and as an anti-proliferative agent. Group: Biochemicals. Alternative Names: 4- [4- [ [ [ [4-Chloro-3- (trifluoromethyl) phenyl] amino] carbonyl] amino] -3-fluorophenoxy] -N-methyl-2-pyridinecarboxamide; 4-[4-[N- (4-Chloro-3-trifluoromethylphenyl) ureido]-3-fluorophenoxy]pyridine-2-carboxylic Acid Methylamide; BAY 73-4506; Fluoro-Sorafenib; Stivarga. Grades: Highly Purified. CAS No. 755037-03-7. Pack Sizes: 25mg, 50mg, 100mg, 250mg, 500mg. Molecular Formula: C??H??ClF?N?O?, Molecular Weight: 482.82. US Biological Life Sciences. |  Worldwide |
| Regorafenib | Regorafenib, also known as BAY 73-4506, is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. Regorafenib is demonstrated to increase the overall survival of patients with metastatic colorectal cancer and has been approved by the US FDA on September 27, 2012. Uses: Antineoplastic agent. Synonyms: 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide; 4-[4-[N'-(4-Chloro-3-trifluoromethylphenyl)ureido]-3-fluorophenoxy]pyridine-2-carboxylic Acid Methylamide; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY 73-4506; BAY 734506; BAY734506; BAY-734506. Grade: >98%. CAS No. 755037-03-7. Molecular formula: C21H15ClF4N4O3. Mole weight: 482.83. |  |
| Regorafenib | Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC 50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3 , PDGFRβ , Kit , RET and Raf-1 , respectively. Regorafenib shows very robust antitumor and antiangiogenic activity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BAY 73-4506. CAS No. 755037-03-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-10331. |  |
Our database is helping our users find suppliers everyday.
